Targeting the HDAC1/SLC30A3/p38 MAPK axis emerges as a potential therapeutic strategy, highlighting SLC30A3’s role in curbing GBM malignancy via MAPK pathway activation [73]. This evidence concerns the gene HDAC1 and glioblastoma.